Almirall to publish clinical trials
Almirall demonstrates its commitment to public transparency and defined ethical principles in performing clinical trials and communication of their results
Trials started from
Barcelona, 27 February.- To the benefit of health professionals and patients, Almirall announces that it will be making public its clinical trials with its own, new research molecules and marketed products, in accordance with recommendations by the EFPIA (European Federation of Pharmaceutical Industries and Associations), included in the Joint position on the disclosure of clinical trial information via clinical trial registries and database, a statement of resolve regarding the above issue.This information will be available, as from February, on the Almirall corporate website.
The initiative corresponds to Almirall’s own policy of transparency and with the joint statement on the dissemination of clinical trials agreed by the European, North American and Japanese pharmaceutical industry associations.
The Almirall corporate website will provide access to physicians, pharmacists and other professionals in the sector, as well as patients themselves, to the clinical trials register and results.This includes details such as the kind and phase of the clinical trial, the medical conditions, dates and territories where the studies are performed, the statistical analyses used, as well as other essential information regarding the trials.
The Clinical Trials Register section will include information about current non-exploratory clinical trials. The space reserved for Results of Clinical Trials will include the conclusions of the non-exploratory trials sponsored by Almirall with drugs approved for commercialisation and that are available in at least one country.
All clinical trials sponsored by Almirall aim to further the progress of scientific knowledge; their results, whether positive or negative, will therefore be published.It must also be highlighted that Almirall will perform clinical research with the highest standards of scientific quality and respect for patients.
Almirall, a leading company committed to health
Almirall is a consolidated international pharmaceutical company that researches, develops and commercialises its own R&D and licensed specialities with the aim of improving health and quality of life.
The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD, psoriasis and rheumatoid arthritis.
Almirall is currently present in approximately 100 countries with its own products and licensed products from other prestigious companies.The company is strengthening its direct presence in